Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Phase 2 Active not recruiting 98 enrolled Emmanuelle Waubant, MD PhD United States Department of Defense · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.

Timeline

Start: 2022-02-16
Primary completion: 2027-02
Completion: 2027-02

Publications

Schoeps VA, Graves JS, Stern WA, Zhang L, Nourbakhsh B, Mowry EM, Henry RG, Waubant E. N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial. Contemp Clin Trials. 2022 Nov;122:106941. doi: 10.1016/j.cct.2022.106941. Epub 2022 Sep 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	N-acetylcysteine	Small molecule	1200 mg	—

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Summary

Timeline

Publications

Drugs

Indications